Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.62 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.62 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 3/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287449 | 1.00 | MMP2 (0.62) | MMP2ADAMTS5NEK1CA2CA7 | |
| SCHEMBL3188265 | 0.88 | AR (0.61) | MMP2ADAMTS5NEK1MMP9ADAMTS4 | |
| SCHEMBL9512132 | 0.86 | MMP2 (0.60) | MMP2ADAMTS5CA2CA7PIN1 | |
| SCHEMBL3192784 | 0.86 | CTSL (0.65) | MMP2NEK1CA2CA7PIN1 | |
| SCHEMBL21808621 | 0.86 | CA2 (0.73) | MMP2NEK1CA2CA7PIN1 | |
| SCHEMBL18328186 | 0.86 | CA2 (0.73) | MMP2NEK1CA2CA7PIN1 | |
| SCHEMBL27633200 | 0.86 | CTSL (0.65) | MMP2NEK1CA2CA7PIN1 | |
| SCHEMBL9512738 | 0.80 | ALDH1A1 (0.57) | MMP2ADAMTS5CA2CA7PIN1 | |
| SCHEMBL3009401 | 0.80 | MMP2 (0.92) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3009406 | 0.80 | MMP2 (0.92) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | BACE1, BACE2, GSAP | MMP2 3089/4885ADAMTS5 1447/4885NEK1 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.